// App-Quantinova.ai

OP023 : A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD)

Researchers

Presenter

  • S Danese

Principal Investigators

  • B Feagan

  • W Sandborn

  • J -F Colombel

  • S Vermeire

  • S Jones

  • K Brennan

  • J Bornstein

Medical Centers

  • Humanities University, IBD Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy

  • University of Western Ontario, Robarts Clinical Trials, London, Ontario, Canada

  • University of California, Inflammatory Bowel Disease Center, Division of Gastroenterology, San Diego, USA

  • Icahn School of Medicine at Mount Sinai, Department of Psychiatry, New York, NY, USA

  • University Hospital CHU of Liege, Gastroenterology, Liege, Belgium

  • Europe Development Centre, Takeda R&D, London, UK

  • Takeda Pharmaceuticals International Co., Cambridge, MA

Locations

  • Italy

  • Canada

  • United States

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved